title: Increased plasma beta-thromboglobulin in patients with coronary artery vein graft occlusion: response to low dose aspirin.
abstract: The therapeutic effect of aspirin on vein graft patency was studied in patients undergoing coronary artery bypass graft surgery. The study design enabled the prospective evaluation of the relation of platelet activation, as measured by plasma beta-thromboglobulin concentration, to subsequent coronary vein graft occlusion. Serial beta-thromboglobulin levels were measured in 105 patients randomized to receive aspirin (324 mg/day) or placebo beginning within 1 h after surgery. Graft patency was assessed angiographically at 1 week and 1 year after surgery. Of 49 patients receiving placebo, 17 (34.7%) had one or more graft occlusions, 6 early, 10 late and 1 with both early and late occlusion. Of 56 patients receiving aspirin, 7 (12.5%) had one or more occlusions, 3 early and 4 late (p less than 0.01). Preoperatively, the beta-thromboglobulin level in surgical patients (29 +/- 13.5 ng/ml) was significantly higher than that of 51 control subjects (22.6 +/- 11.1 ng/ml) (p less than 0.004). Plasma beta-thromboglobulin levels remained comparatively constant at 3 and 12 months after surgery in the 43 patients who had both samples available (p less than 0.001, r = 0.65). The reduction in beta-thromboglobulin concentration from the preoperative level to 12 months postoperatively was greater in the aspirin-treated group (p less than 0.001). Multivariate logistic regression analysis demonstrated a significant association between preoperative beta-thromboglobulin concentration and graft occlusion (p less than 0.02), and aspirin treatment was effective in preventing occlusion when adjusted for the preoperative beta-thromboglobulin level (p less than 0.005). Plasma beta-thromboglobulin concentrations are elevated in patients with coronary artery disease, suggesting ongoing platelet activation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Cardiology, St. Vincent's Hospital, Sydney, New South Wales, Australia.
authors: T P
authors: TP
authors: Gavaghan
authors: J B
authors: JB
authors: Hickie
authors: S A
authors: SA
authors: Krilis
authors: D W
authors: DW
authors: Baron
authors: V
authors: V
authors: Gebski
authors: J
authors: J
authors: Low
authors: C N
authors: CN
authors: Chesterman
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D004691:Endarterectomy; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006083:Graft Occlusion, Vascular / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012501:Saphenous Vein / Q000637:transplantation; D001620:beta-Thromboglobulin / Q000378:metabolism*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D001620:beta-Thromboglobulin; C036309:fibrin fragment D; D001241:Aspirin